Computer-aided Molecular Design of 1H-imidazole-2,4-diamine Derivatives As Potential Inhibitors of Plasmodium Falciparum DHFR Enzyme

Overview

Journal J Mol Model

Publisher Springer

Specialty Molecular Biology

Date 2010 Jun 5

PMID 20524021

Citations 7

Authors

Legesse Adane

Prasad V Bharatam

Affiliations

Soon will be listed here.

Abstract

Design and discovery of new potential inhibitors of Plasmodium falciparum dihydrofolate reductase (PfDHFR), equally active against both the wild-type and mutant strains, is urgently needed. In this study, a computer-aided molecular design approach that involved ab initio molecular orbital and density functional theory calculations, along with molecular electrostatic potential analysis, and molecular docking studies was employed to design 15 1H-imidazole-2,4-diamine derivatives as potential inhibitors of PfDHFR enzyme. Visual inspection of the binding modes of the compounds demonstrated that they all interact, via H-bond interactions, with key amino acid residues (Asp54, Ileu/Leu164, Asn/Ser108 and Ile14) similar to those of WR99210 (3) in the active site of the enzymes used in the study. These interactions are known to be essential for enzyme inhibition. These compounds showed better or comparable binding affinities to that of the bound ligand (WR99210). In silico toxicity predictions, carried out using TOPKAT software, also indicated that the compounds are non-toxic.

Citing Articles

Benzimidazole derivatives as a new scaffold of anticancer agents: Synthesis, optical properties, crystal structure and DFT calculations.

Zouaghi M, Bensalah D, Hassen S, Arfaoui Y, Mansour L, Ozdemir N Heliyon. 2024; 10(12):e32905.

PMID: 39022063 PMC: 11252883. DOI: 10.1016/j.heliyon.2024.e32905.

Identification of CYP3A4 inhibitors as potential anti-cancer agents using pharmacoinformatics approach.

Wanjari P, Rath A, Sathe R, Bharatam P J Mol Model. 2023; 29(5):156.

PMID: 37097473 DOI: 10.1007/s00894-023-05538-z.

Methylenedioxy Piperamide-Derived Compound D5 Regulates Inflammatory Cytokine Secretion in a Culture of Human Glial Cells.

Shahbazi S, Zakerali T Molecules. 2022; 27(11).

PMID: 35684465 PMC: 9182381. DOI: 10.3390/molecules27113527.

2-Benzylidenebenzofuran-3(2)-ones as a new class of alkaline phosphatase inhibitors: synthesis, SAR analysis, enzyme inhibitory kinetics and computational studies.

Ashraf J, Mughal E, Alsantali R, Sadiq A, Jassas R, Naeem N RSC Adv. 2022; 11(56):35077-35092.

PMID: 35493176 PMC: 9042899. DOI: 10.1039/d1ra07379f.

An epigrammatic status of the ''-based antimalarial drugs.

Sharma M, Prasher P RSC Med Chem. 2021; 11(2):184-211.

PMID: 33479627 PMC: 7536834. DOI: 10.1039/c9md00479c.

References

Maitarad P, Saparpakorn P, Hannongbua S, Kamchonwongpaisan S, Tarnchompoo B, Yuthavong Y . Particular interaction between pyrimethamine derivatives and quadruple mutant type dihydrofolate reductase of Plasmodium falciparum: CoMFA and quantum chemical calculations studies. J Enzyme Inhib Med Chem. 2008; 24(2):471-9. DOI: 10.1080/14756360802201223. View

GENTHER C, Schoeny R, Loper J, Smith C . Mutagenic studies of folic acid antagonists. Antimicrob Agents Chemother. 1977; 12(1):84-92. PMC: 352158. DOI: 10.1128/AAC.12.1.84. View

Japrung D, Leartsakulpanich U, Chusacultanachai S, Yuthavong Y . Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination. Antimicrob Agents Chemother. 2007; 51(12):4356-60. PMC: 2167985. DOI: 10.1128/AAC.00577-07. View

Maitarad P, Kamchonwongpaisan S, Vanichtanankul J, Vilaivan T, Yuthavong Y, Hannongbua S . Interactions between cycloguanil derivatives and wild type and resistance-associated mutant Plasmodium falciparum dihydrofolate reductases. J Comput Aided Mol Des. 2009; 23(4):241-52. DOI: 10.1007/s10822-008-9254-z. View

Sirichaiwat C, Intaraudom C, Kamchonwongpaisan S, Vanichtanankul J, Thebtaranonth Y, Yuthavong Y . Target guided synthesis of 5-benzyl-2,4-diamonopyrimidines: their antimalarial activities and binding affinities to wild type and mutant dihydrofolate reductases from Plasmodium falciparum. J Med Chem. 2004; 47(2):345-54. DOI: 10.1021/jm0303352. View

Richard A . Commercial toxicology prediction systems: a regulatory perspective. Toxicol Lett. 1999; 102-103:611-6. DOI: 10.1016/s0378-4274(98)00257-4. View

Bharatam P, Patel D, Iqbal P . Pharmacophoric features of biguanide derivatives: an electronic and structural analysis. J Med Chem. 2005; 48(24):7615-22. DOI: 10.1021/jm050602z. View

Song C, Lim S, Tong J . Recent advances in computer-aided drug design. Brief Bioinform. 2009; 10(5):579-91. DOI: 10.1093/bib/bbp023. View

Canfield C, Milhous W, Ager A, ROSSAN R, SWEENEY T, Lewis N . PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. Am J Trop Med Hyg. 1993; 49(1):121-6. DOI: 10.4269/ajtmh.1993.49.121. View

10.

Sardarian A, Douglas K, Read M, Sims P, Hyde J, Chitnumsub P . Pyrimethamine analogs as strong inhibitors of double and quadruple mutants of dihydrofolate reductase in human malaria parasites. Org Biomol Chem. 2003; 1(6):960-4. DOI: 10.1039/b211636g. View

11.

Schnell J, Dyson H, Wright P . Structure, dynamics, and catalytic function of dihydrofolate reductase. Annu Rev Biophys Biomol Struct. 2004; 33:119-40. DOI: 10.1146/annurev.biophys.33.110502.133613. View

12.

Mui E, Schiehser G, Milhous W, Hsu H, Roberts C, Kirisits M . Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis. 2008; 2(3):e190. PMC: 2254147. DOI: 10.1371/journal.pntd.0000190. View

13.

Adane L, Bharatam P . 3D-QSAR analysis of cycloguanil derivatives as inhibitors of A16V + S108T mutant Plasmodium falciparum dihydrofolate reductase enzyme. J Mol Graph Model. 2009; 28(4):357-67. DOI: 10.1016/j.jmgm.2009.09.001. View

14.

Bharatam P, Sundriyal S . Molecular electrostatic potentials in the design of dendrimers for the delivery of glitazones. J Nanosci Nanotechnol. 2006; 6(9-10):3277-82. DOI: 10.1166/jnn.2006.473. View

15.

Desai P, Patny A, Gut J, Rosenthal P, Tekwani B, Srivastava A . Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory. J Med Chem. 2006; 49(5):1576-84. DOI: 10.1021/jm0505765. View

16.

Adane L, Patel D, Bharatam P . Shape- and chemical feature-based 3D-pharmacophore model generation and virtual screening: identification of potential leads for P. falciparum DHFR enzyme inhibition. Chem Biol Drug Des. 2009; 75(1):115-26. DOI: 10.1111/j.1747-0285.2009.00908.x. View

17.

Lee , Yang , PARR . Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys Rev B Condens Matter. 1988; 37(2):785-789. DOI: 10.1103/physrevb.37.785. View

18.

McKie J, Douglas K, Chan C, Roser S, Yates R, Read M . Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria. J Med Chem. 1998; 41(9):1367-70. DOI: 10.1021/jm970845u. View

19.

Hecht D, Cheung M, Fogel G . QSAR using evolved neural networks for the inhibition of mutant PfDHFR by pyrimethamine derivatives. Biosystems. 2007; 92(1):10-5. DOI: 10.1016/j.biosystems.2007.10.005. View

20.

Vistoli G, Pedretti A, Testa B . Assessing drug-likeness--what are we missing?. Drug Discov Today. 2008; 13(7-8):285-94. DOI: 10.1016/j.drudis.2007.11.007. View